• Alias: CP-675,206; CP-675; anti-CTLA4 human monoclonal antibody CP-675,206
    • A human IgG2 monoclonal antibody directed against the human TCR protein CTLA4 that binds to CTLA4 on activated T-lymphocytes and blocks the binding of the antigen-presenting cell ligands B7-1 (CD80) and B7-2 (CD86) to CTLA4, resulting in the inhibition of CTLA4-mediated downregulation of T-cell activation.
    • Phase 2 in combination with durvalumab in mCRC or NSCLC; phase 1b/2 in combination with durvalumab or anti-PD-L1 inhibitor in gastric or GE junction adenocarcinoma or cutaneous melanoma
    • Recommended phase 2 dose: 1 mg/kg IV every 4 weeks es, then every 12 weeks for 3 doses.
    Other topics in Targeted and Immunotherapy Agents